Skip to main content

Table 2 Univariable and multivariable analysis for factors affecting overall survival

From: Establishment and validation of a prognostic pomogram in unresectable hepatocellular carcinoma treated with intensity modulated radiotherapy: a real world study

Variable

Univariable analysis

Multivariable analysis

HR (95% CI)

p-value

HR (95% CI)

p-value

Age

1.00 (0.99–1.02)

0.869

  

Sex (male vs. female)

1.35 (0.78–2.34)

0.284

  

BMI (> 23 kg/m2 vs. ≤ 23 kg/m2)

0.88 (0.62–1.23)

0.445

  

Smoking (yes vs. no)

1.03 (0.77–1.4)

0.823

  

Drinking (yes vs. no)

0.96 (0.71–1.31)

0.810

  

Hypertension (yes vs. no)

0.92 (0.59–1.44)

0.717

  

Diabetes (yes vs. no)

1.39 (0.88–2.2)

0.156

  

HBsAg (positive vs. negative)

1.16 (0.82–1.66)

0.399

  

Cirrhosis (yes vs. no)

1.29 (0.93–1.8)

0.129

  

MVI (yes vs. no)

1.29 (0.95–1.75)

0.097

  

Extrahepatic metastasis (yes vs. no)

1.36 (1.01–1.84)

0.046

1.27 (0.88–1.83)

0.198

Tumor size (> 6 cm vs. ≤ 6 cm)

1.7 (1.26–2.31)

0.001

0.86 (0.58–1.28)

0.465

Tumor number (> 3 vs. ≤ 3)

2.13 (1.57–2.89)

 < 0.001

1.69 (1.21–2.37)

0.002

BCLC stage C (yes vs. no)

1.54 (1.05–2.25)

0.027

1.09 (0.70–1.72)

0.697

Child Paugh class (B vs. A)

1.47 (1.03–2.12)

0.036

0.94 (0.61–1.45)

0.770

BED (> 60 Gy vs. ≤ 60 Gy)

0.80 (0.59–1.09)

0.161

  

PLT (< 100 × 109/L vs. ≥ 100 × 109/L)

1.82 (1.19–2.79)

0.006

1.74 (1.11–2.73)

0.017

ALC (> 1.8 × 109/L vs. ≤ 1.8 × 109/L)

0.58 (0.39–0.88)

0.010

0.78 (0.50–1.20)

0.260

ANC (≥ 2 × 109/L vs. < 2 × 109/L)

1.54 (0.92–2.59)

0.101

  

Hb (< 131 g/L vs. ≥ 131 g/L)

1.50 (1.11–2.03)

0.009

1.31 (0.92–1.84)

0.131

AST (> 40 U/L vs. ≤ 40 U/L)

1.26 (0.94–1.71)

0.126

  

ALT (> 40 U/L vs. ≤ 40 U/L)

1.03 (0.76–1.4)

0.839

  

ALP (> 150 U/L vs. ≤ 150 U/L)

1.80 (1.31–2.48)

 < 0.001

1.65 (1.15–2.37)

0.006

TBIL (> 21umol/L vs. ≤ 21umol/L)

1.36 (0.97–1.92)

0.076

  

Alb (< 55 g/L vs. ≥ 55 g/L)

1.43 (1.06–1.93)

0.021

1.06 (0.73–1.56)

0.746

PT (> 13 s vs. ≤ 13 s)

1.21 (0.89–1.65)

0.213

  

AFP (≥ 400 ng/ml vs. < 400 ng/ml)

1.45 (1.07–1.98)

0.017

1.52 (1.10–2.10)

0.011

Prior TACE (yes vs. no)

1.04 (0.75–1.43)

0.817

  

Prior surgery (yes vs. no)

0.53 (0.39–0.72)

 < 0.001

0.63 (0.43–0.93)

0.020

Prior immunotherapy (yes vs. no)

1.89 (0.77–4.63)

0.165

  

Combined immunotherapy (yes vs. no)

1.15 (0.65–2.05)

0.627

  
  1. AFP alpha-fetoprotein; BCLC Barcelona Clinic Liver Cancer; BMI Body Mass Index; MVI macrovascular invasion; BED biologically effective dose; TACE transarterial chemoembolization; PLT platelet; ALC Absolute Lymphocyte Count; ANC Absolute Neutrophil Count; Hb Hemoglobin; AST Aspartate aminotransferase; ALT Alanine aminotransferase; ALP alkaline phosphatase; TBIL total bilirubin; Alb Albumin; PT Prothrombin time; HR hazard ratio; CI confidence interval